Complexin (cx) I and cx II are synaptic proteins preferentially expressed by inhibitory and excitatory hippocampal neurons respectively. We previously reported decreased hippocampal formation cx mRNA and protein expression in schizophrenia, with a greater loss of cx II than cx I. The present in situ hybridization study was both an attempt at replication, and an extension to include bipolar and unipolar mood disorders, using sections from the Stanley Foundation brain series. In schizophrenia, both mRNAs were decreased in some hippocampal subfields, especially CA4, but were preserved in subiculum. The cx II/cx I mRNA ratio was unchanged. In bipolar disorder, the mRNAs were reduced in CA4, subiculum and parahippocampal gyrus, with the deficit in subiculum being diagnostically specific. No alterations in cx mRNAs were found in major depression. Treatment of rats with antipsychotics (haloperidol or chlorpromazine) for 2 weeks had no effect on hippocampal cx mRNAs. These data replicate the finding of decreased cx I and cx II expression in the hippocampus in schizophrenia and show a similar or greater abnormality in bipolar disorder. Non-replication of the cx II Ͼ cx I mRNA loss in schizophrenia means that the hypothesis of a preferential involvement of excitatory connections was not supported. The results extend the emerging evidence that altered circuitry may be a component of the neuroanatomy of both schizophrenia and bipolar mood disorder. Molecular Psychiatry (2000) 5, 425-432.
Introduction
There is a growing consensus that the pathophysiology of schizophrenia involves aberrant functional connectivity. 1, 2 The extent to which such an abnormality is 'hardwired', ie is attributable to morphological alterations in neurons and their synaptic connections, is a key question in contemporary neuropathological studies. 3 Molecular techniques for investigating synapses, based upon the expression of gene products targetted to either pre-or post-synaptic domains, have been prominent in this search.
In the hippocampus in schizophrenia, several studies have found decrements in expression and abundance of pre-synaptic proteins such as synaptophysin and SNAP-25. [4] [5] [6] [7] [8] Recently we reported that expression of two other such proteins, complexin (cx) I and its homologue cx II, is also reduced, supporting the existence of synaptic pathology in the disorder. 9 In addition, we found that at both mRNA and protein level, the ratio of the two gene products was altered, with cx II decreased more than cx I. This was noteworthy because of the differential distribution of the two gene products in the hippocampus. Cx I is expressed mainly by interneurons, which are inhibitory, whereas cx II is expressed primarily by granule cells and pyramidal neurons, which are excitatory. [9] [10] [11] [12] [13] Hence the differential changes in cx expression cautiously implied a preferential involvement of hippocampal excitatory connections in schizophrenia.
The present study had three objectives. Firstly, to replicate the cx findings in a separate series of brains. Secondly, to include subjects with bipolar disorder and major (unipolar) depression, to address the diagnostic specificity of the findings. Thirdly, though no relationship between medication history and hippocampal cx expression was apparent in the earlier study, 9 we investigated this further by measuring cx mRNAs in rats administered haloperidol or chlorpromazine.
Methods

Demographic details
Details of the Stanley Foundation brain series are given in Table 1 . Diagnoses of schizophrenia, bipolar disorder and major depression were made according to DSM-IV criteria. All brains had been screened to exclude coincidental neuropathological abnormalities, Not known for one major depression subject. e Chlorpromazine equivalents (grams). and the four groups matched for key demographic details, including RNA quality. 14 
In situ hybridization histochemistry (ISHH)
ISHH conditions and controls for detection and measurement of cx I and cx II mRNAs using 35 S-labelled selective oligonucleotides and film autoradiography, calibrated to 35 SnCi g −1 tissue equivalents, were as described. 9 Three adjacent 14-m pretreated cryosections of the hippocampal formation were hybridized from each subject, with the mean value over each subfield entered for the statistical analysis.
Statistical analysis
All results were submitted to the Stanley Foundation prior to the code being revealed to one of us (PJH) and statistical analysis being carried out. The rest of the research group remain blind for future studies. Comparisons between the four groups were by ANCOVA with age, pH and post mortem interval (PMI) as covariates.
14,15 Significant (␣ Ͻ 0.05) F-ratios were followed by Scheffé tests. In addition, because we had a specific aim to see if the difference between schizophrenics and controls 9 was replicated, we made a separate comparison between these two groups, including analysis of the cx II/cx I mRNA ratio. As in all our studies on this brain series, 16 an a priori decision was made to omit as outliers any individuals with values Ͼ2 SDs from the group mean in a particular subfield.
Rat studies
Adult male Sprague-Dawley rats (n = 8 in each group) were treated for 2 weeks with daily intraperitoneal injections of chlorpromazine (15 mg kg ), or saline and killed 24 h after the last injection. ISHH for cx mRNAs was carried out with homologous rat oligonucleotides on sections from the dorsal hippocampus, as described.
13
Results
The hippocampal distribution of cx I and cx II mRNAs in the human (Figures 1 and 2 ) and rat (data not shown) was as predicted. 9, 13 Hence cx II mRNA could be measured in all major subfields (dentate gyrus, CA4, CA3, CA1, subiculum and parahippocampal gyrus), whilst cx I mRNA could not be measured reliably in dentate gyrus or CA1 because of its minimal expression therein.
The final sample sizes in each group ranged from 13-15, having omitted the outliers, and the occasional instances when sections were torn or folded preventing measurement of a subfield.
In the overall hippocampal ANCOVAs, pH had a significant effect on cx mRNAs (both P Ͻ 0.001), but PMI did not (both P Ͼ 0.2). Cx I mRNA was affected by age (P = 0.012), with inspection of the data showing this reflected a tendency for the mRNA to increase with age in each subfield. 
Complexin I mRNA comparisons between diagnostic groups
The overall ANCOVA showed an effect of diagnosis upon hippocampal cx I mRNA (F 3,226 = 9.19, P Ͻ 0.001). The r 2 value for the model was 0.642 (ie the variables of diagnosis, subfield, age, pH and PMI together predicted 64% of the variance in cx I mRNA).
The ANCOVA for each subfield revealed a difference between groups in subiculum (P = 0.002) and parahippocampal gyrus (P = 0.040) with a trend in CA4 (P = 0.055). The results are shown in Figure 3 . The post hoc Scheffé tests indicated that cx I mRNA was reduced compared to controls in bipolar disorder in CA4, subiculum and parahippocampal gyrus, and in schizophrenia in CA4. The loss of cx I mRNA in the subiculum in bipolar disorder was also significant compared to the schizophrenia and major depression groups (Figure 3c ).
Complexin II mRNA comparisons between diagnostic groups
The overall ANCOVA showed a difference between groups (F 3,334 = 8.30, P Ͻ 0.001), with an r 2 value of 0.888.
As shown in Figure 4 , there were effects of diagnosis in CA4 (P = 0.018), subiculum (P = 0.004) and parahipMolecular Psychiatry pocampal gyrus (P = 0.012). In CA4, cx II mRNA was reduced in schizophrenia and bipolar disorder. In subiculum, it was reduced in bipolar disorder compared to all other groups. In parahippocampal gyrus the decrease was significant only for bipolar disorder compared to controls.
Comparison between controls and schizophrenics
To assess whether we had replicated the finding of decreased cx mRNAs and a lower cx II mRNA to cx I mRNA ratio in schizophrenia relative to controls, we carried out an analysis restricted to these two groups, using the same statistical approach as in the original paper. 9 For cx I mRNA the overall hippocampal ANCOVA showed a difference between groups (F 1,113 = 6.48, P = 0.012) but no diagnosis-by-subfield interaction (F 3,113 = 0.27, P = 0.848). Cx II mRNA differed between the two groups (F 1,170 = 18.78, P Ͻ 0.001) and there was a diagnosis-by-subfield interaction (F 5,170 = 3.00, P = 0.013). As shown in Table 2 , this reflected a decrease of cx II mRNA in schizophrenia in CA4, with similar trends in dentate gyrus, CA3 and parahippocampal gyrus, but no change in CA1 or subiculum. In the four subfields wherein both cx mRNAs could be measured, the ratio between them was unchanged. 
Other influences on complexin mRNAs
There was no effect on cx mRNAs of hemisphere or sex, nor interaction of these variables with diagnosis. Abundance of the mRNAs did not correlate with lifetime antipsychotic exposure, antidepressant or mood stabliser usage, age at onset, or duration of illness. Nor was there any consistent association with family psychiatric history, substance abuse, suicide, or the use of psychotropic medication in the six months before death (data not shown).
Effects of antipsychotics on complexin mRNAs in rat hippocampus
There were no alterations in cx I mRNA or cx II mRNA in any hippocampal subfield measured following treatment with haloperidol or chlorpromazine ( Table 3) .
Discussion
This study has three major findings. Firstly, we replicated the observation that cx I and cx II mRNAs are decreased in the hippocampus in schizophrenia. This provides a further indication of synaptic pathology in the disorder. Secondly, we did not confirm a greater decrement in cx II than cx I mRNA in schizophrenia; in keeping with our previous interpretation, 9 we therefore conclude that this study does not provide evidence for a preferential excitatory involvement in schizophrenia.
Thirdly, hippocampal cx mRNAs are also decreased in bipolar disorder, but not in major depression. Hence, there may be important commonalities in the synaptic pathology of the functional psychoses.
Complexin expression in schizophrenia
A decrease of cx expression can be added to that affecting synaptophysin 4, 5, 7, 8 as a replicated hippocampal synaptic abnormality in schizophrenia. Reductions in expression of these synaptic proteins are not present throughout the cerebral cortex, 17, 18 nor are they merely reflecting a lower hippocampal mRNA content. 19 Nor, indeed, is the loss of cx mRNA uniform across subfields (Figures 3 and 4) . Hence it may be concluded that there is a regionally and molecularly selective impairment of synaptic protein gene expression in the hippocampus in schizophrenia.
Interpreting the biological significance of synaptic protein alterations is not straightforward. Most likely, decreased expression is indicative of alterations in synaptic organisation, specifically a reduced synaptic terminal density. In this respect, the results are likely to be at least partially related to the decrements in neuronal size reported in several studies, 3 since cell body size within a neuronal population is primarily a correlate of axo-dendritic arborization. 20 Other possible interpretations include smaller synaptic terminal size, fewer vesicles per terminal, or abnormalities of tran- scriptional regulation. Moreover, the normal roles of synaptic proteins should not be neglected; ie their decreased expression may be important as a marker of synaptic dysfunction as well as of altered synaptic structural organisation. Notably, the complexins are involved in neurotransmitter release 21 and long-term potentiation, 22 and impairment of either activity as a result of decreased cx availability might contribute to compromised hippocampal functioning.
In two respects we did not replicate our previous cx findings in schizophrenia. Firstly, the finding of a greater decrease of cx II than cx I expression in schizophrenia implied a synaptic pathology which affected excitatory (glutamatergic) connections more than inhibitory (GABAergic) ones. 9 No such differential reduction was seen here (Table 2) ; instead, both markers were affected similarly. One possibility could be demographic differences between the two studies. In particular, the subjects here were 15 years younger, had an earlier mean age of onset (23 vs 29 years), and a correspondingly shorter duration of illness (Table 1) . Perhaps, for example, cx II-related pathology is progressive, whereas cx I alterations are static. However, the cx II: cx I mRNA ratio did not show consistent or significant correlations with age at onset or duration of Molecular Psychiatry schizophrenia (data not shown). The other non-replication concerns the extent and distribution of the alterations. In the first study, cx mRNA reductions were seen in schizophrenia in all subfields and ranged up to 84% (in terms of radioactivity units), 9 whereas here the decreases were less widespread and generally smaller, being maximal for cx I mRNA in CA4 (−50%). Again, demographic factors may be important, or these differences may reflect regression to the mean.
Complexin expression in bipolar disorder
The decreases of cx mRNAs in bipolar disorder were strikingly similar to those seen in schizophrenia (Figures 3 and 4) . Although virtually nothing is known regarding the neuropathology of bipolar disorder, this result is in keeping with recent data suggestive of cytoarchitectural and synaptic abnormalities in mood disorders, both in the prefrontal cortex 17, 23, 24 and hippocampal formation. 8, 25 Such findings suggest that the two major functional psychoses may have key structural elements in common. 26 On the other hand, the unaltered cx mRNA levels in major depression show that the changes are not a non-specific correlate of severe psychiatric illness or its sequelae. The only significant difference between schizophrenia and bipolar dis- order was in the subiculum, wherein cx mRNAs were selectively reduced in bipolar disorder (Figures 3c and  4e) . Replication of this result, and its corroboration by other markers, is necessary before concluding that the anatomical profile of synaptic alterations within the hippocampus differs between the two disorders, and before advocating a particular role for the subiculum in bipolar disorder.
In an immunoblotting study of the cingulate cortex from the same brains, we found that cx II was decreased in all three diagnostic groups compared to controls, but cx I was not affected (unpublished observations). Together with the present results, this suggests that synaptic abnormalities indexed by cx II expression may be widespread within limbic circuits, but that the precise pattern, and the involvement of cx I, reflects an interaction between diagnosis and cytoarchitectural area. Furthermore, cx II levels in the cingulate cortex showed a strong, inverse association with duration of bipolar disorder whereas no such correlations were seen here. This may reflect a difference in the timing or progression of the synaptic abnormalities in the two brain regions. Group comparison by Mann-Whitney test. All P Ͼ 0.4 (two-tailed). Values are optical density units × 100 (mean [SEM] ). There are no significant differences between the groups.
Methodological issues
As described above, age, and especially pH, affected cx mRNAs. The fact that pH had an influence on the mRNAs, even though brains with a low pH or degraded RNA are excluded from this series, 14 emphasises the continuing need to attend to these variables (eg by careful matching and covariate statistics) in gene expression studies. 15 The effect of medication was investigated in several ways: 27 by correlation with cumulative lifetime antipsychotic dose; by comparing subjects according to whether they had ever received antipsychotic, antidepressant or mood-stabilising drugs; whether they had been on treatment within 6 months of death, and by administering haloperidol or chlorpromazine to rats (Table 3) . None of these analyses were positive, and we conclude that medication does not alter hippocampal cx mRNA expression nor, therefore, produce or ameliorate the alterations seen in schizophrenia and bipolar disorder. This is consistent with the lack of antipsychotic effects on synaptophysin mRNA in the hippocampus. 4 The main limitation of this study is that we could not measure the abundance of the encoded proteins because of lack of tissue. However, in the previous study the reductions, and change in ratio, affected cx Molecular Psychiatry protein as well as mRNA. 9 Furthermore, the level of cx mRNAs seen here correlate with the abundance of cx proteins measured in cingulate cortex of the same brains (unpublished observations). Hence cx mRNA and protein expression appear to be co-ordinated, and so a broadly similar pattern of results would be predicted for hippocampal cx proteins. Nevertheless, direct measurement of both gene products should be a goal for all studies wherever feasible.
Summary
The expression of hippocampal cx I and II mRNAs is decreased in schizophrenia and bipolar disorder. The results give a further molecular indication that hippocampal synaptic circuitry is altered in schizophrenia, [3] [4] [5] [6] [7] [8] 28, 29 and support the emerging view that bipolar disorder also has a neuropathological signature. Sustained application of the increasingly sophisticated molecular methods becoming available will be needed to decipher it.
